Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause

Overview of attention for article published in Obstetrics & Gynecology, March 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#29 of 8,982)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 94 news outlets
blogs: 1 blog
policy: 1 policy source

twitter: 12 X users
video: 1 YouTube creator

Citations

dimensions_citation: 30 Dimensions

Readers on

mendeley: 40 Mendeley

Summary News Blogs Policy documents X YouTube Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Præparatanmeldelse Veoza (Fezolinetant)

Cited by Danish Health Authority on 22 Mar 2024

The Danish Health Authority advises municipalities and regions and comes up with recommendations, guidelines and action plans, to promote public health and create a good framework for the healthcare system in Denmark.

Præparatanmeldelse Veoza (Fezolinetant)

Cited by Danish Health Authority on 05 Feb 2024

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.